Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Robert A. Scott, M.D., appointed Chief Medical Officer of Cerenis Therapeutics

Toulouse, France & Ann Arbor, Michigan, January 23, 2008 - Cerenis Therapeutics SA, a privately held pharmaceutical company developing HDL compounds for the treatment of cardiovascular and metabolic diseases, today announced the appointment of Rob Scott, M.D., as the company's chief medical officer. Dr. Scott brings to the company more than 20 years of experience leading global cardiovascular drug development programs through clinical development to highly successful commercialization.

Most recently Dr. Scott served as executive vice president of research and development at AtheroGenics, Inc., a pharmaceutical company focused on the treatment of chronic inflammatory diseases. At AtheroGenics Dr. Scott oversaw development efforts in the areas of atherosclerosis, diabetes, rheumatoid arthritis and asthma. Previously, Dr. Scott was worldwide therapeutic head of the cardiovascular and metabolic group at Pfizer. In that role Dr. Scott was responsible for the development teams that produced: NORVASC®, the most-prescribed drug for high blood pressure; LIPITOR®, the most prescribed drug for high LDL cholesterol and the world's best-selling drug; CADUET®, the first combination drug for the simultaneous management of two separate disease states; and other products for the treatment of diabetes and cardiac arrhythmias.

“We are honored to have Dr. Scott on board as our CMO. His deep expertise in developing novel cardiovascular treatments and his highly impressive track record in guiding blockbuster therapies through clinical development will make him a great asset to our company. For Cerenis, the appointment of Dr. Scott is a crucial step as we advance from a preclinical to a clinical development focus,” said Jean-Louis Dasseux, Ph.D., President and CEO of Cerenis.


About Cerenis Therapeutics
Cerenis Therapeutics is a pharmaceutical company focused on the discovery, development and commercialization of breakthrough HDL-related therapies for the treatment of cardiovascular and metabolic diseases. Based on pioneering research conducted by the Cerenis team of world leaders in HDL therapy, the company is pursuing a range of HDL product candidates that are positioned to represent major advances in patient care and significant commercial opportunities in the treatment of cardiovascular and metabolic diseases. Cerenis has operations in Ann Arbor, Michigan and Toulouse, France. For further information please visit

For further information, please visit

- ends –

Further enquiries:


College Hill
Tel: +44 (0)20 7866 7856

Holly Griffiths, Senior Account Executive

Tony Stephenson, Senior Account Manager


Berry & Company Public Relations
Tel: (212) 253-8881

Publisher Contact Information:

College Hill
+44 (0)20 7866 7856

Company profile of Cerenis Therapeutics SA
Past press releases of Cerenis Therapeutics SA.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 25€24.0MInternet commerce
Nov 8N/AOther Computers & Electronics
Nov 5€2.1MAudio/Video
Nov 5€5.2MOther Computers & Electronics
Nov 5€0.4MInternet services
Nov 5€1.3MSecurity
Nov 5€1.5MAudio/Video

For information on Europe's most extensive database on technology funding click here!


Press Releases

Sep 30
tetavi raises $6 million to help more companies bring 3d holograms ...

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Mar 31
the fit allocates chf 100'000 to comppair technologies

Jan 29
yumpingo raises $10m to transform guest experiences in restaurants

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.